University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: a subset of cells that drive the disease appear to have a much slower metabolism than most other tumors cells.

Nations that consume a lot of milk and milk products also tend to have a lot of Nobel laureates among their populations, suggest the authors of a letter, published in Practical Neurology. Research published last year in the New England Journal of Medicine reported a strong association between a nation's chocolate consumption and Nobel laureate prowess, speculating that the flavonoid content of chocolate was behind the boost in brain power.

It is perhaps impossible to overstate the importance of the tumor suppressor gene p53. It is the single most frequently mutated gene in human tumors. p53 keeps pre-cancerous cells in check by causing cells, among other things, to become senescent - aging at the cellular level. Loss of p53 causes cells to ignore the cellular signals that would normally make mutant or damaged cells die or stop growing.

Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals of Oncology.

Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on British Medical Journal. Although the absolute risk for individuals is low, it is still something doctors and patients should be aware of, say the researchers.

A team, led by senior author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, found that the diabetes drug metformin works in a different way than previously understood.

Researchers at Mayo Clinic in Florida have identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases. This fast-growing, often lethal cancer is resistant to conventional chemotherapy.